The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs

Laura Tucker, Alexander Allen, David Chandler, Coziana Ciurtin, Andrew Dick, Amy Foulkes, Nicola Gullick, Philip Helliwell, Deepak Jadon, Gareth Jones, Stuart Kyle, Vishnu Madhok, Neil McHugh, Andrew Parkinson, Tim Raine, Stefan Siebert, Catherine Smith, William Tillett, Laura C. Coates* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


PsA is a chronic, inflammatory, musculoskeletal disease affecting approximately one quarter of people with the skin condition psoriasis [1, 2]. PsA is a highly heterogeneous disease, encompassing diverse musculoskeletal manifestations or ‘domains’ resulting from disease activity in different tissues. These include peripheral arthritis, spondylitis (axial inflammation), dactylitis (inflammation of the whole digit) and enthesitis (inflammation where a tendon, ligament or joint capsule insert to the bone). Unlike RA, there is a significant variability in clinical presentation of PsA. Individuals with PsA may have different domains involved and drugs have different levels of effectiveness on each domain. It is therefore essential that clinical guidelines for the treatment selection in PsA include disease phenotype and differential effect of medication.
Original languageEnglish
Pages (from-to)e255-e266
Number of pages12
JournalRheumatology (Oxford, England)
Issue number9
Early online date31 May 2022
Publication statusPublished - 1 Sept 2022

Bibliographical note

We gratefully acknowledge the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the members of their Treatment Recommendations working group who shared extracted data on treatment RCTs for this project.

Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript. Expenses for travel were paid by the British Society for Rheumatology.

Data Availability Statement

All relevant data produced during the guideline development process are presented in this manuscript or in the accompanying supplementary material.


  • biologics
  • dactylitis
  • enthesitis
  • guideline
  • management
  • PsA
  • psoriasis
  • recommendations
  • targeted synthetic DMARDs
  • treatment


Dive into the research topics of 'The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs'. Together they form a unique fingerprint.

Cite this